Hospital
Kaiser Foundation Hospitals
Kaiser Foundation Hospitals was paid $9.30M by Medicaid between Jan 2018 and Dec 2024, across 127 billing codes. Its largest line is 99284, emergency room visit (serious) — 26% of everything it billed.
33Billing provider infoKAISER FOUNDATION HOSPITALS
SOUTH SAN FRANCISCO, CA 94080
SOUTH SAN FRANCISCO, CA 94080
33aNPI1982774337assigned 11/09/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$9.30M
24GClaims260,290
24DCodes billed127
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#186 of 410
Median peer was paid$6.90M
This provider vs. median1.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 14,230 | $211K | |
| 2019 | 24,339 | $258K | |
| 2020 | 18,958 | $441K | |
| 2021 | 29,798 | $929K | |
| 2022 | 41,868 | $1.07M | |
| 2023 | 61,567 | $1.62M | |
| 2024incomplete | 69,530 | $4.77M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 26% | 5,590 | 5,206 | $2.39M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 15% | 4,719 | 4,522 | $1.37M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 10% | 6,394 | 6,167 | $974K |
| 0450 | Emergency room services | 6.9% | 14,799 | 13,282 | $646K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.5% | 2,091 | 2,060 | $516K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 4.7% | 5,457 | 4,903 | $438K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.7% | 593 | 568 | $436K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.1% | 2,024 | 1,982 | $192K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 2.0% | 2,896 | 2,826 | $187K |
| 71046 | Radiologic examination, chest; 2 views | 1.7% | 3,620 | 3,556 | $160K |
| 71045 | Radiologic examination, chest; single view | 1.6% | 3,796 | 3,677 | $152K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 1.3% | 2,447 | 2,420 | $123K |
115 more codes
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | 1.0% | 1,180 | $94K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 3,999 | $92K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 4,204 | $90K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 551 | $80K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 6,203 | $80K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 13,755 | $66K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 292 | $57K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,315 | $57K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,632 | $56K |
| 73630 | <1% | 899 | $51K | |
| 80051 | <1% | 8,852 | $46K | |
| 76830 | Ultrasound, transvaginal | <1% | 426 | $39K |
| 72100 | <1% | 410 | $34K | |
| 83880 | <1% | 2,201 | $34K | |
| 73030 | <1% | 500 | $33K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,541 | $32K |
| 82565 | <1% | 10,518 | $32K | |
| 73610 | <1% | 606 | $32K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 10,987 | $30K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 586 | $27K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,209 | $27K |
| 73564 | <1% | 278 | $26K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 5,927 | $23K |
| 84520 | <1% | 8,944 | $23K | |
| 82247 | <1% | 6,748 | $23K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 2,274 | $22K |
| 73560 | <1% | 398 | $22K | |
| 84460 | <1% | 6,477 | $22K | |
| 73130 | <1% | 318 | $22K | |
| 82947 | <1% | 8,930 | $22K | |
| 83690 | <1% | 5,068 | $22K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 237 | $22K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 473 | $21K |
| 84450 | <1% | 6,012 | $20K | |
| 93976 | <1% | 161 | $20K | |
| 84075 | <1% | 5,525 | $19K | |
| 81001 | <1% | 8,646 | $18K | |
| 84484 | <1% | 3,014 | $17K | |
| 93971 | <1% | 82 | $12K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,119 | $11K |
| 83735 | <1% | 2,803 | $11K | |
| 86900 | <1% | 296 | $11K | |
| 73562 | <1% | 130 | $11K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,191 | $10K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,248 | $10K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,723 | $10K |
| 73110 | <1% | 161 | $9K | |
| 73502 | <1% | 141 | $9K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,058 | $9K |
| 99070 | <1% | 3,988 | $8K | |
| 0270 | <1% | 1,030 | $8K | |
| 82077 | <1% | 657 | $7K | |
| 81003 | <1% | 4,821 | $7K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 217 | $6K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 217 | $6K |
| 84702 | <1% | 527 | $6K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,269 | $6K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,445 | $6K |
| 87631 | <1% | 219 | $5K | |
| J3490 | Unclassified drugs | <1% | 1,702 | $5K |
| 85610 | <1% | 1,720 | $5K | |
| 73140 | <1% | 56 | $4K | |
| 87088 | <1% | 1,309 | $4K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 25 | $4K |
| 85652 | <1% | 2,310 | $4K | |
| 86850 | <1% | 154 | $4K | |
| 86901 | <1% | 297 | $4K | |
| 82962 | <1% | 1,412 | $3K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 662 | $3K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 189 | $3K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 170 | $3K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 59 | $2K |
| 82248 | <1% | 491 | $2K | |
| 87040 | <1% | 239 | $2K | |
| 72040 | <1% | 13 | $2K | |
| 0637 | <1% | 13,755 | $2K | |
| 85027 | <1% | 669 | $2K | |
| 84100 | <1% | 644 | $2K | |
| 99199 | Unlisted special service, procedure or report | <1% | 35 | $2K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 161 | $2K |
| 73080 | <1% | 27 | $2K | |
| 76770 | <1% | 12 | $2K | |
| 84703 | <1% | 321 | $1K | |
| 71101 | <1% | 12 | $1K | |
| 83605 | <1% | 251 | $1K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 584 | $1K |
| 82310 | <1% | 317 | $1K | |
| 84132 | <1% | 297 | $1K | |
| 76536 | <1% | 26 | $1K | |
| T1999 | Miscellaneous therapeutic items and supplies, retail purchases, not otherwise classified; identify product in "remarks" | <1% | 45 | $1K |
| 80306 | <1% | 151 | $1K | |
| 0710 | <1% | 412 | $1K | |
| 85379 | <1% | 252 | $971.96 | |
| 87449 | <1% | 86 | $971.00 | |
| 74018 | <1% | 26 | $875.75 | |
| 87324 | <1% | 72 | $861.52 | |
| Z7502 | <1% | 43 | $629.30 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 165 | $538.79 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 47 | $492.06 |
| 0250 | <1% | 1,833 | $455.68 | |
| 71250 | <1% | 12 | $429.02 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 77 | $393.60 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 103 | $280.04 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 48 | $242.15 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 74 | $222.14 |
| 85730 | <1% | 33 | $216.00 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 139 | $179.03 |
| 85007 | <1% | 107 | $119.84 | |
| 86140 | <1% | 22 | $104.58 | |
| 0258 | <1% | 128 | $25.20 | |
| 88304 | <1% | 27 | $10.90 | |
| 76376 | 0% | 75 | $0.00 | |
| 0370 | 0% | 299 | $0.00 | |
| 96376 | 0% | 16 | $0.00 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGROEPPER, RON (SENIOR VICE PRESIDENT, AREA MANAGER)
| Provider | Location | Paid |
|---|---|---|
| Kaiser Foundation Hospitals | San Francisco, CA | $14.97M |
| Kaiser Foundation Hospitals | San Francisco, CA | $633K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.